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Abstract: A major limitation of biological therapeutics is their propensity for degradation particularly in aqueous 
solutions hence resulting in their short shelf-life. In this study, the stability of trastuzumab (Herceptin
®
) intravenous (i.v.) 
solutions, an IgG1 monoclonal antibody (mAb), indicated for the treatment of HER2 positive breast cancer, stored under 
refrigerated conditions, was evaluated over 28 days. No change in visual appearance or average particle size was 
observed. The pH values of the trastuzumab i.v. solutions remained stable over time. Interestingly, no change in 
trastuzumab monomer concentration was observed throughout the 28-day study, as determined by SEC-HPLC. SDS-
PAGE showed only a monomer band corresponding to the molecular weight of trastuzumab. Circular dichroism spectra 
obtained following 28-day storage demonstrated integrity of the secondary structural conformation of trastuzumab. 
Results from this study show that trastuzumab i.v. solutions remain physically and structurally stable on storage at 2-8°C 
for 28 days. These findings suggest that trastuzumab in solution may not be as sensitive to degradation as expected for a 
mAb and therefore may have important implications in extending trastuzumab shelf life for clinical use and reducing 
associated healthcare cost. 
Keywords: Trastuzumab, stability, protein aggregation, SEC, particle size, SDS-PAGE, Circular dichroism. 
INTRODUCTION 
Biological therapeutics are increasingly utilised in the 
clinical setting due their specificity to the target site, hence 
leading to lower adverse events and toxicity. In 2008, 21 
monoclonal antibodies (mAbs) were approved in the US 
with over 200 mAb candidates undergoing clinical study [1]. 
A major disadvantage of biological therapeutics is their 
susceptibility to rapid physical, chemical and thermal 
degradation [2, 3], thereby limiting their shelf-life and 
adding to the cost of therapy. Most of the therapeutic mAbs 
are commercially available as lyophilised preparations in 
multi-dose vials to be aseptically reconstituted before use. 
Once reconstituted, usually it is further diluted under aseptic 
conditions, to provide titratable individualised doses for 
patients. These aqueous dilute solutions of proteins are 
particularly vulnerable to instability from various types of 
stressors including shear, thermal, and microbiological and 
hence caution is recommended during their reconstitution 
and handling to prevent full or partial denaturation and/or 
aggregation of these molecules.  
Aggregation is a major response of mAbs when subjected 
to stress of any type and can result in significant loss of 
biological activity or can result in immunogenic reactions 
which may be life-threatening [4-6]. Misfolding or 
denaturation of the protein, leading to the formation of 
aggregates, may also occur upon storage and is accelerated 
by a number of factors including heating, agitation and 
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packaging materials [7]. In a clinical setting the stability of 
the mAb solution, before administration to the patients, is 
checked by visual inspection for discoloration and presence 
of sediments, aggregates/particulate matter. Traditionally a 
visibly clear solution is considered a stable product. 
However Schellekens et al. [8] suggest that smaller 
aggregates which are invisible to the human eye, may be 
present and as these may be inactive or immunogenic, they 
are important to characterise. 
Thermal and chemical stressors have been shown to dis-
rupt the secondary structure of mAbs with impact on its 
physical, chemical stability and hence biological activity and 
toxicity [9-11]. The concentration of the protein and of 
formulation excipients such as surfactants in the final 
solution have been shown to influence the stability of the 
protein. At high concentration of 1.5 mg/mL (10 M), pro-
teins such as IgG1 type antibody was reported to exhibit a 
self-stabilizing ability as a result of its surfactant activity 
[12].  
While the lyophilised mAb products generally have a 
shelf-life of 18-48 months, the manufacturers recommend a 
shelf-life of only 24-48 hours for the reconstituted and 
diluted products, which often leads to wastage and has 
important cost implications limiting access to such treatment. 
Recently, studies on various mAbs have demonstrated 
stability beyond their use date. Reconstituted bevacizumab 
stored in vials and syringes at 4
o
C showed 9.6% and 8.8% 
degradation respectively after 3 months [13]. Chen et al. [14] 
reported less than 10% bevacizumab degradation at 6 months 
when stored in multi-dose vials at 4
o
C. Moreover, Ikesue  
et al. [15] reported that aseptically diluted Cetuximab and 
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Panitumumab solutions at 2 and 2.5 mg/mL were stable for 
14 days at 4
o
C when stored in PVC bags. Similarly, Kupfer 
et al. [16] reported that alemtuzumab stored in infusion bags 
was stable for 14 days. We previously reported that exposure 
of trastuzumab i.v. solutions to various shear stressors such 
as sonication, spray drying or freeze thawing had no effect 
on the aggregation or its structural integrity and this was 
consistent with no significant reduction in the biological 
activity of trastuzumab [17]. Trastuzumab is a recombinant 
humanised IgG1 monoclonal antibody indicated for the 
treatment of HER2 positive breast cancer and more recently 
for the treatment of metastatic HER2 positive gastric cancer 
[17, 18].  
In the present study, trastuzumab was aseptically 
reconstituted and diluted to 0.4-4 mg/mL according to the 
manufacturer’s instructions and stored under refrigerated 
conditions of 2-8
o
C. The effect of storage time on the 
physical and structural stability of the i.v. solutions was 
examined. In addition, the influence of shaking and exposure 
to increasing temperatures on the trastuzumab i.v. solutions 
was studied in order to understand the sensitivity of the 
tratsuzumab i.v. solutions to such potential stressors as may 
be encountered during their handling and transport in 
practice. 
EXPERIMENTAL 
For each test, n=6 trastuzumab samples were used, unless 
otherwise stated. Changes in colour, cloudiness or presence 
of particulate matter were examined by visual observation. 
Particle size analysis was carried out using a Zetasizer 
NanoZS (Malvern Instruments, Worcestershire, UK) (n=3 
samples) and pH was measured using a calibrated CyberScan 
510 pH meter. Structural stability was evaluated by size ex-
clusion chromatography (SEC-HPLC), Sodium dodecyl Sul-
fate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and 
Circular dichroism (CD) analysis as described previously by 
Pabari et al. [17] and Tang et al. [19]. 
Statistics 
Data is expressed as mean ± standard deviation (SD), 
unless otherwise indicated. Statistical analysis was 
conducted using SPSS (PASW Statistics 18), using Repeated 
Measures ANOVA, One-Way ANOVA and student’s t-tests 
(unpaired and paired) where appropriate, p values < 0.05 are 
considered significant. 
RESULTS AND DISCUSSION 
Visual Appearance and Particle Size Analysis 
Trastuzumab i.v. solutions were found to be clear, col-
ourless solutions with no visible particulate material present 
at any time point tested, irrespective of concentration. Parti-
cle size analysis showed no significant change in particle 
size over the 28-day period regardless of trastuzumab con-
centrations, confirming absence of aggregates over the 
study period (Repeated Measures ANOVA, p>0.05, n=3) 
(Table 1).  
pH Stability Profile  
The pH of freshly prepared trastuzumab i.v. solutions 
was in the range of 5.81 to 6.17 which was within the manu-
facturer’s recommended pH range of approximately 6.0. The 
measured pHs of all solutions remained stable over time and 
were within the pH range measured for corresponding 
freshly prepared trastuzumab i.v. solutions over the study 
period; pH range of 6.13 – 6.26, 6.01 – 6.09 and 5.58 – 5.97 
at 4.0, 1.0 and 0.4 mg/mL respectively (Fig. 1). 
SEC-HPLC 
Trastuzumab i.v. solutions of 0.4, 1 or 4 mg/mL stored at 
2-8ºC showed no significant change in trastuzumab mono-
mer concentration over the 28 days studied (Fig. 2). Impor-
tantly, no new peaks were observed over the time course 
indicating absence of soluble aggregates or degradants (Fig. 3). 
Kupfer et al. [16] reported that alemtuzumab in infusion-
bags stored over 14 days at 6
o
C, at room temperature and on 
a vibrating plate was physically and chemically stable.  
SDS-PAGE Analysis  
SDS-PAGE analysis confirmed the data observed by 
SEC-HPLC. A single band at ~150 kDa, corresponding to 
the molecular weight of intact trastuzumab monomer was 
obtained for all test solutions (Fig. 4). Importantly, there was 
no evidence of reduced trastuzumab or the presence of high 
molecular weight species (HMWS), signifying the absence 
of molecule aggregation. 
Legends: (a) 4 mg/mL at Day 0. Lanes (1) Molecular 
marker, (2) Saline, (3 & 4) control, (5-10) sample 1-6; (11 & 
12) reduced trastuzumab controls, (13 & 14) reduced sam-
ples (1 & 2) (b) 4 mg/mL, (c) 1 mg/mL, (d) 0.4 mg/mL at 
Day 28. Lanes (1) Molecular marker, (2) Saline, (3) control, 
(4-9) sample 1-6, (10) reduced trastuzumab control, (11-12) 
reduced samples (1 & 2).  
Table 1.  Particle Size (nm) of Trastuzumab i.v. Solutions, Stored at 2-8°C (mean ± SD, n=3). 
Trastuzumab Day 0 Day 2 Day 5 Day 8 Day 15 Day 28 
0.4 mg/mL 12.35 ± 0.40 12.16 ± 1.44 11.56 ± 0.51 12.75 ± 1.57 NM* 11.97 ± 0.92 
1 mg/mL 11.62 ± 12 11.64 ± 0.62 11.71 ± 0.51 NM* NM* 11.32 ± 0.47 
4 mg/mL 11.24 ± 0.25 11.16 ± 0.07 11.13 ± 0.05 11.14 ± 0.12 11.87 ± 0.75 11.22 ± 0.12 
*NM: (Not Measured). 
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Fig. (1). pH profile of 0.4 – 4 mg/ml trastuzumab i.v. solutions stored at 2-8°C (n = 6). 
 
 
Fig. (2). Concentration-time profile of trastuzumab monomer in i.v. solutions stored at 2-8°C (n = 6). 
 
 
Fig. (3). SEC-HPLC chromatograms of trastuzumab i.v. solutions after storage at 2-8°C over 28 days (n = 6). 
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Fig. (4). SDS-PAGE analysis of trastuzumab i.v. solutions stored at 2-8°C over 28 days. 
 
Circular Dichroism  
The CD spectrum of the standard trastuzumab i.v. solu-
tions showed a wavelength at zero intensity of 209.1-
210.1nm, spectra minima at 217.0-217.2 nm and a broad 
shoulder at 227.4-228.6 nm (Fig. 5), similar to that reported 
for IgG1 molecules and demonstrates a dominance of -
sheet secondary structural conformation [10, 17]. No change 
in ellipticity or shift in the wavelength was observed over the 
28-day stability study period indicating that trastuzumab 
maintained its native conformation (Fig. 5).  
Influence of Shaking Stress  
Shaking resulted in a 2-fold increase in the average parti-
cle size of trastuzumab at the lowest concentration of 0.4 
mg/mL (p<0.05) (Table 2), probably due to dimerization of 
trastuzumab. Shaking stress subjects proteins to a high level 
of air-water interfaces hence exposing the hydrophobic core 
of the protein to air and resulting in partial unfolding, aggre-
gation and precipitation [9]. Non-ionic surfactants in protein 
formulations accumulate at the air-liquid interface and there-
fore protect the protein against interface related stress [9]. 
Mahler et al. [12] found that a polysorbate concentration of 
0.005%w/v was sufficient to prevent protein aggregation 
regardless of the antibody concentrations while Kiese et al. 
[20] detected the presence of soluble aggregates at 0.0025% 
w/v of polysorbate 20 for a 10 mg/mL of an IgG1 antibody. 
The trastuzumab i.v. solutions used in our study contained 
polysorbate 20 at 0.0005 to 0.005%w/v for 0.4 to 4 mg/mL, 
respectively. At 4 mg/mL trastuzumab concentration, the
 
Fig. (5). CD spectra of trastuzumab i.v. solutions on storage at 2-8
o
C over 28 days.  
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Table 2.  Influence of Physical and Thermal Stressors on the Average Particle Size (nm) of Trastuzumab (Mean± SD). 
Trastuzumab Native (n = 6) Shaking (n = 6) 35°C (n = 3) 50°C (n = 3) 65°C (n = 3) 75°C (n = 3) 
0.4 mg/mL 11.95 ±1.13 24.61 ±8.88 13.48 ±1.20 12.94 ±1.66 12.87 ±1.56 85.16 ±22.57 
4 mg/mL 11.22 ±0.10 11.53 ±0.13 11.22 ±0.11 11.32 ±0.13 11.38 ±0.11 93.52 ±27.82 
 
 
Fig. (6). CD spectra of trastuzumab, (a) 0.4 mg/mL and (b) 4 mg/mL subjected to elevated temperatures. 
 
surfactant concentration was sufficient to prevent aggrega-
tion, however at 0.4 mg/mL, trastuzumab aggregation was 
observed on shaking possibly as a result of the lower concen-
tration of polysorbate 20.  
Influence of Elevated Temperatures on Trastuzumab 
Stability  
Trastuzumab solutions showed no increase in particle 
size up to a temperature of 65
o
C (Table 2). At 75°C trastu-
zumab solutions became turbid, indicating the formation of 
insoluble aggregates. On centrifugation, particle size analysis 
showed the presence of soluble aggregates in the clear su-
pernatant (Table 2). 
CD spectrum of trastuzumab remained almost unchanged 
with increasing temperatures up to 65
o
C, as was previously 
reported by Vermeer et al. [10] (Fig. 6). Further elevation of 
temperature to 75°C resulted in a marked decrease in the 
wavelength at zero intensity, indicating a loss of ordered 
structure. In addition, a decrease in intensity of the broad 
shoulder at ~228
 
nm reflected an alteration of trastuzumab 
secondary structural conformation, attributable to a small 
transition from -turn conformation to random coil struc-
tures.  
Trastuzumab i.v. solutions were found to be physically 
and structurally stable on storage and when subject to shak-
ing and thermal stresses. This stability may be related, in part 
to the inherent structural stability of trastuzumab molecule 
and partly through the protective effect of other formulation 
excipients such as polysorbate 20, L-histidine and ,-
trehalose dehydrate present in Trastuzumab (Herceptin
®
, 
Roche) [21].  
CONCLUSIONS 
The results of this study show that sterile i.v. solutions of 
trastuzumab remained physically and structurally stable fol-
lowing storage at 2-8
o
C over 28 days. This is in agreement 
with previous literature reports of the stability of other mAbs 
upon storage. Importantly in our study, trastuzumab exhib-
ited resistance to conformational change and physical altera-
tion when subjected to shaking and thermal stressors similar 
or in excess of those encountered in every day clinical prac-
tice. The findings from this study suggest that trastuzumab in 
solution may not be as sensitive to degradation as expected 
for a mAb. This may have important implications in 
extending the shelf life of trastuzumab and other therapeutic 
monoclonal antibodies in clinical practice and therefore war-
rants further exploration.   
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